
Paras Biopharmaceuticals Finland specializes in microbial-based biologics, leveraging proprietary technologies like Diabrid®, Noblecleav®, and Cytofold StructQuant® to produce complex recombinant proteins efficiently.
Established in 2012, the company focuses on biosimilar development (e.g., Romiplostim, Teriparatide, Anakinra), recombinant bioprocess enzymes (RapidEK® and RapidTEV®), and CDMO services for microbial biologics.
With a state-of-the-art facility in Finland, Paras Biopharma provides end-to-end solutions from feasibility studies to large-scale manufacturing. Recognized by global clients for delivering high-quality biologics,
Paras Biopharma is committed to advancing therapies for oncology, rare diseases, and metabolic disorders.
Address
OuluFinland